Fig. 2: MACC1 and S100A4 robustly identify high risk CRC patients. | Oncogene

Fig. 2: MACC1 and S100A4 robustly identify high risk CRC patients.

From: Combinatorial treatment with statins and niclosamide prevents CRC dissemination by unhinging the MACC1-β-catenin-S100A4 axis of metastasis

Fig. 2

IHC of MACC1 and S100A4 in each 2 tumors of non-metastasized and metachronously metastasized primary tumors confirms overexpression of both biomarkers in CRC that yielded metachronous metastases well after surgical removal of the primary tumor (A). MACC1 and S100A4 expressions correlate in CRC tumors. Gene expression levels were analyzed in three additional cohorts of 44, 54 and 117 CRC tumors, respectively. Co-expression was examined with Spearman correlation, and we found a positive correlation of MACC1 and S100A4 expression levels in all datasets (B–D). Kaplan–Meier analysis for MFS and OS of patients based on the MACC1-S100A4 combination panel, test for significance with log rank (Mantel-Cox) test. Combined overexpression of MACC1 and S100A4 was associated with dismal MFS and OS in primary CRC tumors (E), and high levels of MACC1 and S100A4 mRNA transcripts detected in liquid biopsies (preoperative blood samples) predicted poor OS (F). Significant intergroup differences are indicated with asterisks, where applicable.

Back to article page